Fig. 3

Doxorubicin downregulates Vimentin and various aggresome-promoting factors. U266B1 cells were treated with 6.25 nM bortezomib or a combination of 6.25 nM bortezomib and 1 μΜ doxorubicin, followed by Western blot analysis to assess the protein levels of key aggresome components, including Vimentin (a structural component of the aggresome), aggresome-promoting factors such as misfolded protein recognition proteins, motor proteins involved in misfolded protein transport, and aggresome clearance factors (A). The relative protein levels were quantified and plotted, with statistical significance indicated (B). Statistical significance was determined using t-tests, with *p < 0.05, **p < 0.01, and ***p < 0.001. All experiments were performed independently three times